<DOC>
	<DOCNO>NCT00216203</DOCNO>
	<brief_summary>Both pemetrexed cetuximab single agent activity NSCLC non-overlapping toxicity profile . While 2-drug combination therapy proven superior single agent therapy first-line setting NSCLC , phase III trial report second-line setting . Therefore , purpose study determine feasibility combine drug , assess toxicity profile , determine MTD evaluate activity combination expand phase II setting . If combination appear promising activity , evaluation regimen may warrant compare single agent pemetrexed cetuximab alone .</brief_summary>
	<brief_title>Pemetrexed Plus Cetuximab Patients With Recurrent Non Small Cell Lung Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study . Week 1 ( day 1 ) : - Cetuximab 400mg/m2 Week 2 ( Cycle 1 , Day 1 ) : - Cetuximab 250mg/m2 plus premetrexed assign dose level . Patients treat cetuximab day 1 , 8 , 15 21 day cycle . Patients treat pemetrexed day 1 21 day cycle maximum 6 cycle . Acceptable toxicity SD , PR CR : treat 6 cycle continue cetuximab weekly PD excess toxicity Performance status : ECOG 0-2 Life expectancy : At least 12 week Hematopoietic : - ANC &gt; 1,500/mm3 - Platelets &gt; 100,000/mm3 Hepatic : - Bilirubin le equal upper limit normal ( ULN ) - Aspartate aminotransferase ( AST ) &lt; 1.5 X ULN . AST may &lt; 5 X ULN patient liver metastases - Alkaline phosphatase &lt; 5 X ULN Renal : - Calculated creatinine clearance &gt; 45 mL/min ( Cockcroft-Gault ) Cardiovascular : - No significant history uncontrolled cardiac disease ( i.e. , uncontrolled hypertension , unstable angina , congestive heart failure ) Pulmonary : - Not specify</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologic cytologic diagnosis NSCLC Recurrent metastatic disease amenable curative therapyMeasurable disease accord RECIST At least one prior platinum contain regimen either locally advanced metastatic disease Prior chemotherapy must complete least 21 day prior register protocol therapy subject must recover acute toxicity effect regimen Ability willingness interrupt aspirin nonsteroidal antiinflammatory agent 5day period Prior radiation therapy allow &lt; 25 % bone marrow Negative pregnancy test No active infection opinion investigator would compromise subject 's ability tolerate therapy . No serious concomitant systemic disorder would compromise safety subject compromise subject 's ability complete study , discretion investigator . No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer subject diseasefree least 2 year . No major thoracic abdominal surgery within 30 day prior register protocol therapy . No current breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>